This article is the first in a series of comparative analyses between two pharmaceutical companies. These articles will compare two stocks that focus on specific therapeutic areas. It is my ...

Johnson & Johnson and Pfizer both highlighted new data with BCMA-targeting bispecific antibodies in patients with relapsed or refractory multiple myeloma (RRMM) at ASCO, previewing a future ...

Executives mingled with North Carolina leaders in the city of Wilson to ceremonially break ground on Johnson & Johnson’s ...

Johnson & Johnson and Pfizer are two of the world's largest pharmaceutical companies with diversified healthcare portfolios. J&J operates through pharmaceuticals and medical devices divisions. In ...

Pfizer (NYSE:PFE) has named James List, a former Johnson & Johnson (NYSE:JNJ) executive, as the company’s new chief internal ...

Pfizer has vaulted ahead with its respiratory syncytial virus (RSV) vaccine, closing the gap with GlaxoSmithKline and Johnson & Johnson as the companies strive to bring the first licensed shot to ...

Before joining Pfizer, List headed the cardiovascular and metabolism unit at Johnson & Johnson's Janssen division, where he was responsible for the discovery and development of new medicines in ...

March 6 (Reuters) - Pfizer (PFE.N), opens new tab on Thursday named James List as the head of the drugmaker's Internal Medicine portfolio, where he will oversee the development of its closely ...